Objective-The Wnt/wingless signaling antagonist DKK1 (dickkopf-1) regulates platelet-mediated inflammation and may contribute to plaque destabilization. We hypothesized that DKK1 would be associated with cardiovascular outcomes. Approach and Results-We determined DKK1 levels in serum samples obtained before randomization, at discharge, and 1 and 6 months in a subset of 5165 patients with acute coronary syndromes in the PLATO trial (Platelet Inhibition and Patient Outcomes; NCT00391872). The median (interquartile range) DKK1 concentrations were 0.61 (0.20-1.27) ng/mL at baseline and increased during follow-up. The hazard ratio (95% CIs) for the composite end point (cardiovascular death, nonprocedural spontaneous myocardial infarction, or stroke) during 1 year of follow-up, per 50% increase in baseline DKK1 concentration, was 1.06 (1.02-1.10), P=0.0011, and remained significant in fully adjusted analysis with 14 conventional clinical and demographic and 6 biochemical variables, including NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-TnT (high-sensitivity troponin T), and GDF-15 (growth differentiation factor 15; 1.05 [1.00-1.09]; P=0.028). This association was mainly driven by the association with cardiovascular death, where a gradual increase in event rates was observed with increasing quartiles of DKK1 (2.7%, 3.0%, 4.3%, and 5.0%) and remained significant and unmodified in fully adjusted analysis (hazard ratio, 1.10 [1.04-1.17]; P=0.002). Change in DKK1 and levels at 1 month were unrelated to outcomes. A modifying effect of ticagrelor on DKK1 discharge levels was observed but not associated with prognosis. Conclusions-In patients with acute coronary syndromes treated with dual antiplatelet treatment, admission DKK1 levels were independently associated with a composite of cardiovascular death, myocardial infarction, or stroke and with cardiovascular death alone. Visual Overview-An online visual overview is available for this article.
A therosclerosis is a chronic disease characterized by the interaction between lipid accumulation, inflammation, and vascular remodeling that promotes plaque progression, leading to complications like acute coronary syndrome (ACS) and acute ischemic stroke. 1 Activated platelets are important in thrombus formation during ACS. However, these cells also release and express inflammatory mediators that promote inflammatory responses in adjacent monocytes/ macrophages and endothelial cells, contributing to further plaque progression and rupture. These interactions may represent a vicious cycle, playing a pathogenic role in triggering of the ACS. 2, 3 Recent evidence suggests that the Wnt/wingless signaling pathways are important modulators of inflammation. 4 Multiple families of secreted antagonists, including DKK (dickkopf), regulate these pathways. 5 Several studies have demonstrated that platelet-and endothelial-derived DKK1 (dickkopf-1) may promote leukocyte migration, endothelial activation, and inflammation and contribute to the progression of atherosclerotic lesions. 6, 7 More recently, DKK1 was found to promote the injury response during cardiac ischemia after experimental myocardial infarction (MI), 8 suggesting a potential important role for DKK1 in the acute phase after ACS, which could influence long-term prognosis.
Increased DKK1 has been demonstrated in clinical atherosclerosis, with particularly high levels in advanced and unstable disease, 7 as also observed in acute ischemic stroke. 9, 10 However, although Wang et al 11 showed that increased serum DKK1 within 24 hours of admission was an independent predictor of long-term major cardiovascular events in 291 patients with ACS, data on the association between DKK1 levels and outcome in ACS are generally lacking, especially in the context of other important biomarkers with prognostic importance, including NT-proBNP (N-terminal pro-B-type natriuretic peptide), hs-TnT (high-sensitivity troponin T), and GDF-15 (growth differentiation factor 15). Moreover, aspirin reduced DKK1 levels in healthy controls 7 and patients with type 2 diabetes mellitus (DM), 12 whereas glycoprotein IIb/IIIa antagonists reduced DKK1 levels in a small ACS population (n=24), 13 emphasizing the potential role of platelet inhibition in modifying DKK1 levels.
Based on the functional role of DKK1 in regulating platelet-mediated inflammation and its pathophysiological role during plaque destabilization, we hypothesized that DKK1 could aid in risk prediction, as well as provide a target for future antiplatelet therapy in ACS. The PLATO trial (Platelet Inhibition and Patient Outcomes) encompassed a broad ACS population and proved ticagrelor to be superior to clopidogrel in reducing the composite end point of cardiovascular mortality, MI, or stroke. 14, 15 In the current PLATO substudy, we evaluated serum DKK1 levels on admission and during 6 months of follow-up after ACS, together with important prognostic biomarkers, in relation to the composite end point of cardiovascular death, spontaneous MI (sMI), and stroke.
14,15 Finally, we explored the changes over time in DKK1 concentrations from admission through 6 months of follow-up.
Methods
Because of the sensitive nature of the data collected for this study, requests to access the dataset from qualified researchers trained in human subject confidentiality protocols may be sent to Lars Wallentin at lars.wallentin@ucr.uu.se.
Design and Study Population
The randomized, placebo-controlled PLATO trial (NCT00391872) included a total of 18 624 patients with ACS. 14, 15 The patients presented with either ST-segment-elevation ACS or non-ST-segment-elevation ACS and were randomized to either clopidogrel or ticagrelor treatment in addition to optimal medical therapy, including aspirin, and optional invasive therapy. 14, 15 Patients were recruited between October 2006 and July 2008 and were followed for ≤12 months after ACS.
Venous blood samples were obtained from all patients at randomization as part of the main study. In addition, a predefined substudy with serial blood sampling was conducted at selected sites aiming to obtain samples at baseline and during follow-up, at discharge and after 1 month, from at least 4000 patients and from at least 3000 of these patients also at 6 months. 14, 15 All patients at these selected sites were continuously invited to the substudy, and inclusion of new patients proceeded until it was estimated that at least 3000 patients would be available for blood sampling at 6 months. From this serial study cohort, we in the current study analyzed all available samples at baseline, discharge, and 1 and 6 months to avoid any selection bias. The overall aims of the biomarker substudy program have previously been published. 14, 15 The study adhered to the Declaration of Helsinki, the research protocol was approved by national and institutional regulatory and ethics committees, and written informed consent was obtained from the patients.
End Point Definition and Follow-Up
The prespecified primary end point of the present substudy was the composite of cardiovascular death (defined as any cardiovascular cause of death, sudden death, or death without an attributable noncardiovascular cause), sMI (nonprocedure related, nonfatal, MI type 1), or stroke within 1 year of follow-up.
14 All end points in the PLATO trial were centrally adjudicated by an independent and clinical events adjudication committee blinded to patient treatment.
14

Sampling and Laboratory Analysis
Baseline venous blood samples were obtained within 24 hours of admission, before the administration of study medication. The venous blood was allowed to clot and serum centrifuged, isolated and serum samples locally frozen in aliquots and stored at −70°C in a central repository in Uppsala Biobank until biochemical analyses were performed. DKK1 concentrations were determined by enzyme-linked immunoassay (R&D Systems, Stillwater, MN). Intra-assay and interassay coefficients for DKK1 were 3.9% and 7.2%, respectively. We detected no significant diurnal or postprandial variation in DKK1 with a mean intraindividual coefficient of variation of 10.0%, P=0.20, when comparing 4 samples over 24 hours in 13 individuals. Postprandial variation (n=13; fasting versus nonfasting) had a mean intraindividual coefficient of variation of 6.7%, P=0.57. Detection limit was 75 pg/mL defined as 3×SD of assay buffer (n=10). No effect of 3 freeze and thaw cycles was observed (n=2, thawed 3×, mean cardiovascular 7.7%). Storing of the samples at bench for 4 h at room temperature had no effects on levels of DKK1 (n=2, cardiovascular 8.9%).
hs-TnT, NT-proBNP, and cystatin C were determined with sandwich immunoassays on the Cobas Analytics e601 Immunoanalyzer (Roche Diagnostics, Mannheim, Germany). White blood cell count and hs-CRP (high-sensitivity C-reactive protein) were analyzed at the UCR Laboratory, Uppsala, Sweden, with a spectrophotometric analysis (Architect, Abbott, IL). GDF-15 was measured with a precommercial assay (Roche Diagnostics) using a monoclonal mouse antibody for capture and a monoclonal mouse antibody fragment for detection in a sandwich assay format. The results of these analyses in relation to outcomes and effects of study treatment have previously been reported. 16 
Statistical Analysis
DKK1 concentrations at all time points are presented as medians with interquartile ranges (IQRs). The changes of DKK1 concentration over time were tested by Wilcoxon signed-rank test. Baseline characteristics are presented by DKK1 quartile groups. Categorical baseline variables are presented as frequencies and percentages and compared by quartile groups of DKK1 using χ 2 tests. Continuous baseline variables are presented as medians and IQRs and compared by quartile groups of DKK1 using Kruskal-Wallis statistical test. Biomarkers were log transformed to obtain approximate normal distribution. The relationship between natural log transformed DKK1 and baseline characteristics and biomarkers was assessed by multivariable linear models. We calculated geometric means using the antilogarithms of the model-adjusted means (ie, predicted marginal means) and subsequently compared geometric means between groups (eg, men/ women) using ratios.
Time to event or censoring was calculated using randomization date or date of 1-month follow-up visit, respectively, as day 0 and last date of follow-up or noncardiovascular death as censoring day. Crude event rates at 1 year, by DKK1 quartile groups at baseline, were estimated, as well as Kaplan-Meier event rates. The functional form of the relationship between DKK1 and outcomes was explored using cumulative sums of martingale residuals and restricted cubic splines. 19 The association of DKK1 concentrations (ln transformed) and change in DKK1 levels between baseline and 1 month, with the composite end point of cardiovascular death, sMI, or stroke, and secondly, these components individually, as well as bleeding were assessed by multivariable Cox proportional hazards models, with the hazard based on a 50% elevation in DKK1 concentration (see the online-only Data Supplement for further details). Separate models for admission and 1-month levels of DKK1 were developed. Baseline DKK1 was not included in the model evaluating the impact of change in DKK1 and outcome. Six models, with incremental addition of covariates, were used. Model 1 included the randomized treatment (ticagrelor or clopidogrel). Model 2 added clinical baseline risk factors: age, sex, body mass index, DM, chronic kidney disease, hypertension, smoking status, type of ACS, and history of heart failure, MI, percutaneous coronary intervention, CABG (coronary artery bypass grafting), stroke, or peripheral artery disease. Model 3 included all variables from model 2 together with hs-CRP and white blood cell. Model 4 included all the previously mentioned covariates, with the addition of cystatin C-a marker of kidney dysfunction. Model 5 included all variables in addition to hs-TnT and NT-proBNP. Model 6 included all variables and GDF-15. Results are presented as estimated hazards ratios and 95% CIs.
The effects of DKK1 levels on outcomes in relation to predefined subgroup factors (ie, randomized treatment, ACS type, invasive/noninvasive in-hospital treatment approach, DM, sex, and smoking) were evaluated using Cox proportional hazards models, including quartiledivided DKK1 levels, the respective subgroup factor, and the DKK1 subgroup factor interaction term as independent variables. The proportional hazards assumption was assessed by visual inspection of Schoenfeld residual plots. Two-sided P of <0.05 was considered to be statistically significant, and there were no adjustments for multiple comparisons. All statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, NC).
Results
DKK1 at Baseline in Relation to Baseline Characteristics
Baseline DKK1 concentrations were available in 5165 patients, with a median (IQR) of 0.61 (0.20-1.27) ng/mL. The blood samples for DKK1 analysis were collected 15 hours (IQR, 8-21 hours) after the index event, that is, 10 hours (IQR, 3-17 hours) after admission. Baseline characteristics in the current substudy and in the total PLATO population are shown in Table  I in the online-only Data Supplement and were similar except for more frequent ST-segment-elevation MI and lower hs-TnT and NT-proBNP in the current subpopulation. GRACE (Global Registry of Acute Coronary Events) and TIMI (Thrombolysis in Myocardial Infarction) risk scores were equal. The onlineonly Data Supplement shows that baseline characteristics of the patients in the treatment groups were similar.
Baseline characteristics by DKK1 quartile group are presented in the Table and show that higher DKK1 levels were associated with several demographic features and several biomarkers. The 5 strongest predictors of baseline DKK1 (Table  III in 
DKK1 Concentrations During Follow-Up
During 6 months follow-up, DKK1 levels were significantly higher at discharge, 1.01 (0.46-1.57) ng/mL (P<0.0001 versus baseline; n=4598), further higher at 1 month, 1.18 (0.71-1.69) ng/mL (P<0.0001 versus baseline; n=4272), and stayed elevated at 6 months, 1.14 (0.65-1.62) ng/mL (P<0.0001 versus baseline; n=3117; Figure 1 ). Patients treated with ticagrelor as compared with clopidogrel displayed lower DKK1 levels at discharge and a similar trend at 1 and 6 months (Table IV in the online-only Data Supplement), although this did not correspond to an interaction with outcome (Table V in the onlineonly Data Supplement). The predictors of DKK1 levels at 1-month follow-up were distinct from those at baseline with few associations with other circulating biomarkers, with an inverse association with IL (interleukin)-6 in addition to higher levels of white blood cell and a higher frequency of in-hospital invasive treatment and smoking.
DKK1 and Cardiovascular Outcomes
During follow-up, the primary end point was observed in 436 (8.4%) patients. Restricted cubic spline analysis revealed a nonlinear association between DKK1 levels at baseline and incidence of the primary end point (Figure 2A ). Crude event rates were lower for quartile 1 (6.6%) of baseline DKK1 but similar for the higher quartiles (8.8%, 9.1%, and 9.4% for quartiles 2-4; Figure 2C ). There were no interactions between DKK1 levels and outcomes by randomized treatment, and the unadjusted and randomized treatment-adjusted associations between DKK1 and outcome were the same. The randomized treatment-adjusted hazard ratios, therefore, reflect the univariate quantitative relationship between DKK1 and clinical outcome. As shown in Figure 3A , the randomized treatmentadjusted hazard ratio (95% CIs), per 50% increase in baseline DKK1 concentration, was 1.06 (1.02-1.10), P=0.0011. The association remained significant after adjustment for clinical characteristics, inflammatory and cardiac biomarkers, and GDF-15 (1.05 [1.00-1.09]; P=0.028).
Assessment of the individual components of the primary outcome revealed that the association with DKK1 was driven by the effects on cardiovascular death (n=193). Restricted cubic spline analysis revealed a more linear association between DKK1 levels at baseline and incidence of cardiovascular death (Figure 2B) . A gradual increase in event rates was observed with increasing quartiles of DKK1 (2.7%, 3.0%, No associations between DKK1 at baseline and sMI (n=243), stroke (n=62), or bleeding (n=114) were observed (Table VI in the online-only Data Supplement). Figure I in the online-only Data Supplement shows baseline levels of DKK1 in patients who experienced or did not experience clinical outcomes. There were no interactions between DKK1 levels and outcomes by type of ACS (ST-segmentelevation or non-ST-segment-elevation ACS), in-hospital invasive treatment approach, DM, sex, or smoking except for a higher incidence of stroke in women with high DKK1 levels at baseline. Further, patients with DM and high levels of DKK1 were at particularly high risk for the primary outcome and sMI (Table V in the online-only Data Supplement).
Change in DKK1 Concentrations, 1-Month Levels, and Outcome
No association between change in DKK1 levels from baseline to 1 month or DKK1 levels at 1 month and any outcome after this time point was observed ( Figure 3 ; Table VI in the onlineonly Data Supplement).
Discussion
Admission levels of serum DKK1 were independently associated with increased risk of the primary end point, and in particular, cardiovascular death, in the current substudy of patients with ACS treated with dual antiplatelet therapy. The association was independently associated with outcome even after multivariable adjustment for clinical variables and for biomarkers of inflammation, kidney function, and myocardial dysfunction and myocardial necrosis. The DKK1 concentrations increased during follow-up, but the levels at 1 month were unrelated to outcome. A modifying effect of ticagrelor on discharge level was observed, but this did not impact prognosis. Our study suggests that DKK1 could be an independent risk predictor following ACS, potentially reflecting its pathophysiological role in this process.
Patients with angina pectoris are characterized by increased serum DKK1, with particularly high levels in those with unstable disease 7 as also observed in admission samples in smaller studies from patients with MI 20 and acute ischemic stroke, 9, 10 although not in a cohort of 100 young MI survivors (<40 years of age). 21 The only previous study evaluating circulating DKK1 levels in relation to outcome after ACS enrolled 291 patients and found that serum DKK1 within 24 hours of admission was an independent predictor of 2-year major cardiovascular events. 11 Our study of 5165 patients with ACS confirmed that elevated DKK1 levels on admission were associated with future cardiovascular death. Notably, the magnitude of this association was only marginally affected by adjustment for other important biomarkers, including NT-proBNP, hs-TnT, GDF-15, and cystatin C, which display independent associations with cardiovascular death in this study, [16] [17] [18] 22 indicating that DKK1 may exert effects via pathways not reflected by established prognostic biomarkers. In contrast to serum, we previously found similar plasma levels of DKK1 in patients with coronary artery disease and matched controls 7 indicating that serum and plasma may at least partly reflect different pools of DKK1. Thus, although levels in plasma could reflect readily available bioactive DKK1, serum levels reflect the capacity to release DKK1 from platelets during coagulation ex vivo, which could also be relevant in vivo by influencing inflammatory responses during myocardial remodeling.
Platelets and endothelial cells are important sources of DKK1, which may enhance the inflammatory NFκB (nuclear factor kappa-light-chain-enhancer of activated B cells) pathway in platelet-activated endothelial cells. 7 Furthermore, increased DKK1 immunostaining was shown in platelet aggregates at the site of plaque rupture in patients with ST-segmentelevation MI, suggesting that platelet-mediated DKK1 release during plaque destabilization could contribute to an exaggerated inflammatory response and promote adverse myocardial remodeling after ACS 23 with consequent poor prognosis. 24, 25 In addition, experimental studies implicate DKK1 in ischemic damage by demonstrating that global ischemia induced a rapid increase in DKK1 (6 hours), which preceded ischemic neuronal damage, 26 whereas treatment of ischemic animals with DKK1 antisense protected vulnerable hippocampal neurons. 27 More recently, administration of DKK1 immediately after MI in mice promoted ischemic injury through downregulation of the Wnt coreceptors LRP5 and LRP56 (low-density lipoprotein receptor-related protein 5/6), promoted DNA damage, and increased fibrotic and hypertrophic cardiac markers in the infarcted and noninfarcted region leading to cardiac dysfunction. 8 Taken together, we speculate that the association between admission levels of DKK1 and cardiovascular death could be related to DKK1 release during plaque rupture or subsequent platelet activation, which again promotes endothelial activation with further DKK1 release. This DKK1-mediated inflammatory loop might contribute to cardiac ischemia during ACS with adverse effects on myocardial and vascular remodeling and future prognosis. The mechanism of DKK1's possible effects in the acute phase of ACS and potential modulation by anti-ischemic therapy merits further investigation. Still, because change in DKK1 was not associated with future outcome, DKK1 is more likely to be a marker than a therapeutic target.
Our finding that DKK1 levels peaked and then remained stable from 1 month during long-term follow-up reinforces previous results in young MI survivors. 21 However, there were distinct differences in associations between DKK1 levels and other clinical and in particular biochemical parameters, such as IL-6 at baseline and 6 months of follow-up. The reason for this pattern is at present not clear but could mirror that in contrast to IL-6 release, different pathways for DKK1 release are operating during the acute phase as compared with a more stable phase after 1 month. Whereas enhanced serum levels of DKK1 and other platelet-derived inflammatory mediators could indicate a moderate degree of platelet activation, decreased serum levels could reflect sustained platelet activation with platelet degranulation and with tapering of platelet-derived mediators at the site of inflammation, as well as decreased release during ex vivo coagulation. Thus, the poor prognosis associated with high admission DKK1 levels could reflect enhanced release from endothelial cells promoted by degranulated platelets. During follow-up, the increase in DKK1 levels could, therefore, possibly reflect a decrease in platelet activation with less degranulated platelets, whereas the attenuating effects of ticagrelor on DKK1 levels could reflect an inhibiting effect on DKK1 release from endothelial cells or platelets. The lack of association between change in DKK1 from baseline to 1 month or 1 month levels and outcome suggests that these processes for DKK1 release in the stable phase have little to do with adverse outcome. However, these postulated complex interactions (Figure 4 ) need to be further studied and clarified. Nonetheless, our findings strongly support that measurement of serum DKK1 levels during the acute phase in ACS could give important prognostic information, potentially through its ability to mirror activation of several important pathogenic pathways during the acute event.
Patients with DM tend to have higher platelet reactivity 28, 29 and are at increased risk of ischemic events post-ACS. 30, 31 Several studies have demonstrated increased circulating DKK1 in patients with DM, in particular in the presence of platelet activation 12 and abnormal carotid intima media thickness, 32 and a modest association between DM and increasing DKK1 was observed in the present study. More importantly, DM patients with the highest levels (ie, quartile 4) were at increased risk of reaching the primary end point, mainly because of a higher incidence of stroke. Thus, our findings could suggest that abnormal platelet activation and release of DKK1 during ACS could increase the risk of recurrent cardiovascular events in patients with DM.
The current study provides insights to the role of DKK1 in a population with ACS, but it has some limitations. The PLATO trial comprises a broad population with ACS.
However, because mortality was lower in the group randomized to ticagrelor, a survival bias with ticagrelor may have been present. However, because this would only affect nonfatal outcomes, and DKK1 was most strongly associated with cardiovascular death, it is unlikely this should influence our results. Baseline characteristics in the treatment arms were similar, and no interaction between randomized treatment, DKK1, and outcome was observed. Some differences in baseline characteristics compared with the main PLATO trial were noted, but risk as estimated by GRACE and TIMI risk scores was similar. However, our cohort is a representative population with ACS (ie, no inclusion/exclusion criteria to expect any particular selection).
Conclusions
In patients with ACS and dual antiplatelet treatment, we observed an independent association between admission levels of DKK1 and risk of cardiovascular death, indicating that levels of DKK reflect other pathways and mechanisms than established and novel biomarkers including, NT-proBNP, troponin, and GDF-15. Change in DKK1 during 1-month follow-up was not associated with future adverse outcome suggesting that DKK1 is more likely to be a marker than a therapeutic target. The clinical use of DKK1 as a potential biomarker with regard to decision-making in patients with ACS on optimal antithrombotic therapy needs to be further assessed and chartered in independent studies.
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